GlassScriptPhysician profile
April Danielle Daniel
NPI 1508479379
$5,345.41
in general payments reported to CMS, 2019-2025
39 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,476 · 2022: $1,327 · 2023: $1,155 · 2024: $1,195 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $709.67 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $531.89 | 2021-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $500.44 | 2021-2025 | |
| Lilly USA, LLC | $464.47 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $434.15 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Mylan Specialty L.P. | $358.94 | 2021-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $289.01 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.45 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $170.80 | 2021-2025 | Veozah |
| Sumitomo Pharma America, INC. | $165.18 | 2023-2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $159.86 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.52 | 2022-2024 | |
| Allergan, INC. | $117.78 | 2022 | |
| Dexcom, INC. | $105.05 | 2023 | Dexcom G7 Gss (161) |
| Amgen INC. | $103.55 | 2021-2024 | Repatha |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.